文献速递糖尿病

1型糖尿病合并严重低血糖的单纯胰岛移植受者5年良好结局相关因素:协作性胰岛移植登记处分析

Factors associated with favourable 5 year outcomes in islet transplant alone recipients with type 1 diabetes complicated by severe hypoglycaemia in the Collaborative Islet Transplant Registry.
PubMed 文献 · Diabetologia · 2022-10-06

在协作性胰岛移植登记处(CITR)中,对1999至2015年间移植、随访至少1年的398例非尿毒症性1型糖尿病合并严重低血糖事件的单纯胰岛移植受者进行分析,发现受者年龄≥35岁、输注胰岛总量≥325,000胰岛当量、诱导免疫抑制采用T细胞清除和/或TNF-α抑制、维持治疗同时使用mTOR抑制剂和钙调神经磷酸酶抑制剂这四个因素与最高良好结局率相关;满足全部四个因素(4CFF)的126例受者中,末次输注后5年95%无严重低血糖事件,53%脱离胰岛素,且安全性可接受。

要点

  • 4CFF组末次胰岛输注后5年95%无严重低血糖事件,53%脱离胰岛素。
  • 4CFF组76%的受者HbA1c<53 mmol/mol(7.0%),73%同时无严重低血糖事件。
  • 4CFF组与<4CFF组每例受者发生导致后遗症、残疾或死亡的严重不良事件发生率分别为0.056例/人和0.074例/人。

核心结论

  • 在1型糖尿病合并严重低血糖事件的受者中,满足4CFF的胰岛移植在末次输注后5年使95%的受者免于严重低血糖事件,并对血糖控制产生大幅且显著的获益,对该1型糖尿病亚组安全性可接受。

研究设计与样本

  • 回顾性分析协作性胰岛移植登记处(CITR)中1999至2015年间移植、随访至少1年的398例非尿毒症性1型糖尿病合并严重低血糖事件的单纯胰岛移植受者。

主要发现

  • 满足4CFF的受者(N=126)末次胰岛输注后5年95%无严重低血糖事件,76% HbA1c<53 mmol/mol(7.0%),73% HbA1c<53 mmol/mol(7.0%)且无严重低血糖事件,53%脱离胰岛素,均显著高于其余受者(<4CFF;N=272)。
  • 4CFF组每例受者发生导致后遗症、残疾或死亡的 procedural 及免疫抑制相关严重不良事件发生率为0.056例/人,<4CFF组为0.074例/人,两组均低。

关键数值与推荐

  • 与最高良好结局率相关的四个因素为:受者年龄≥35岁;输注胰岛总量≥325,000胰岛当量;诱导免疫抑制采用T细胞清除和/或TNF-α抑制;维持治疗同时使用mTOR抑制剂和钙调神经磷酸酶抑制剂。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Islet transplantation has been studied in small cohorts of recipients with type 1 diabetes complicated by severe hypoglycaemic events (SHEs). We determined factors associated with favourable outcomes in a large cohort of recipients reported to the Collaborative Islet Transplant Registry (CITR). METHODS: In 398 non-uraemic islet transplant alone (ITA) recipients with type 1 diabetes and SHEs, transplanted between 1999 and 2015 and with at least 1 year follow-up, we analysed specified favourable outcomes against each of all available characteristics of pancreas donors, islet grafts, recipients and immunosuppressive regimens, as well as immunosuppression and procedure-related serious adverse events (SAEs). RESULTS: Four factors were associated with the highest rates of favourable outcomes: recipient age ≥35 years; total infused islets ≥325,000 islet equivalents; induction immunosuppression with T cell depletion and/or TNF-α inhibition; and maintenance with both mechanistic target of rapamycin (mTOR) and calcineurin inhibitors. At 5 years after the last islet infusion, of the recipients meeting these four common favourable factors (4CFF; N=126), 95% were free of SHEs, 76% had HbA1c <53 mmol/mol (7.0%), 73% had HbA1c <53 mmol/mol (7.0%) and absence of SHEs, and 53% were insulin independent, significantly higher rates than in the remaining recipients (<4CFF; N=272). The incidence of procedural and immunosuppression-related SAEs per recipient that resulted in sequelae, disability or death was low in both the 4CFF (0.056 per person) and <4CFF (0.074 per person) groups. CONCLUSIONS/INTERPRETATION: In recipients with type 1 diabetes complicated by SHEs, islet transplantation meeting 4CFF protected 95% from SHEs at 5 years after the last islet infusion and exerted a large and significant benefit on glycaemic control, with an acceptable safety profile for this subgroup of type 1 diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Hering BJ, Ballou CM, Bellin MD, et al. Factors associated with favourable 5 year outcomes in islet transplant alone recipients with type 1 diabetes complicated by severe hypoglycaemia in the Collaborative Islet Transplant Registry. Diabetologia. 2022. PMID: 36201044. doi:10.1007/s00125-022-05804-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。